Cannabinoid-derived EHP-101 Eased Fibrosis in Systemic Sclerosis Mouse Model, Emerald Reports

Emerald Health Pharmaceuticals’ lead cannabinoid-derived treatment candidate, EHP-101, has shown potential to prevent skin and lung tissue scaring in a mouse model of systemic sclerosis, the company reports.

Emerald also claims that EHP-101’s therapeutic activity is similar or superior to that seen in ajulemic acid, also known as lenabasum — a potential treatment being developed by Corbus Pharmaceuticals that is currently in Phase 3 trial, called RESOLVE-1 (NCT03398837), in people with diffuse cutaneous systemic sclerosis.

RESOLVE-1 is enrolling patients at sites across the U.S.; a separate Phase 2 study has moved

...read more at https://sclerodermanews.com/2018/07/05/cannabinoid-derived-ehp-101-eased-fibrosis-inflammation-in-mice-emerald-health-reports/